Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: allovir.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/26/2023 | $17.00 → $1.00 | Buy → Underperform | BofA Securities |
| 12/22/2023 | Outperform → Market Perform | Leerink Partners | |
| 12/22/2023 | Overweight → Underweight | JP Morgan | |
| 12/22/2023 | Overweight → Neutral | Piper Sandler | |
| 8/18/2023 | $17.00 | Buy | BofA Securities |
| 2/10/2022 | $32.00 → $30.00 | Outperform | SVB Leerink |
| 1/18/2022 | $48.00 → $45.00 | Overweight | Morgan Stanley |
| 12/17/2021 | $37.00 → $32.00 | Outperform | SVB Leerink |
| 11/8/2021 | $41.00 → $37.00 | Outperform | SVB Leerink |
| 10/19/2021 | $48.00 | Overweight | Morgan Stanley |
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio
Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. 22, 2023 (GLOBE NEWSWIRE) -- AlloVir, Inc. (NASDAQ:ALVR), an allogeneic T cell immunotherapy company, today provided an update on its three Phase 3 clinical trials with posoleucel, an investigational off-the-shelf multi-virus-s
AlloVir, Inc. (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET. A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. About AlloVir AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. T
-- Posoleucel, a highly innovative off-the-shelf, multi-virus-specific investigational T cell therapy, continues to advance in three distinct, Phase 3, first-to-market indications in immunocompromised patients -- Enrollment in posoleucel pivotal Phase 3 multi-virus prevention, virus-associated hemorrhagic cystitis and adenovirus studies all progressing with topline data for all three studies anticipated in the second half of 2024 --Progressing global commercial launch planning for posoleucel across all indications -- As of September 30, 2023, AlloVir had cash, cash equivalents, and short-term investments of $213.3 million providing runway through all pivotal trial data readouts Allo
AlloVir, Inc. (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference Fireside Chat: Monday, September 11, 2023 at 4:55 pm ET H.C. Wainwright 25th Annual Global Investment Conference Presentation: Tuesday, September 12, 2023 at 12:00 pm ET A live webcast and archived replay of these presentations will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. About AlloVir AlloVir is a leading late-clinical stage cell therapy company foc
Company's three Phase 3 global registrational trials for its allogeneic, off-the-shelf, virus-specific T cell therapy, posoleucel, in three distinct, first-to-market indications in allo-HCT patients continue to enroll, with data anticipated in second half of 2024 Positive data from the Phase 2 trial of posoleucel for treatment of BK viremia in kidney transplant recipients presented orally at late-breaking session at the American Transplant Congress (ATC 2023) ALVR106, a multi-respiratory virus-specific T cell therapy targeting human metapneumovirus, influenza, parainfluenza, and respiratory syncytial virus, completed enrollment in the dose-escalation (Part A) portion of the Phase 1b/2a
AlloVir, Inc. (NASDAQ:ALVR), a late clinical-stage cell therapy company, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.75 per share. The gross proceeds to AlloVir from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be $75.0 million. All shares in the offering are to be sold by AlloVir. In addition, AlloVir has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close
AlloVir, Inc. (NASDAQ:ALVR), a late clinical-stage cell therapy company, today announced that it has commenced a proposed underwritten public offering of $75.0 million of shares of its common stock. AlloVir also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of its common stock offered in the public offering. All of the shares in the proposed offering are to be sold by AlloVir. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. J.P. Morgan, Morgan Stanley and BofA Securities
Posoleucel demonstrated clinically meaningful reductions in BK viral load as compared to placebo with the greatest antiviral activity seen among patients with higher viral loads and those who received more frequent posoleucel dosing At Week 24, the percentage of patients with a ≥1-log viral load reduction in the biweekly dosing group was 50% (10/20) vs. 28% (5/18) in the monthly dosing group and 14% (2/14) in the placebo group In the high viral load stratum (≥10,000 copies/mL), 69% (11/16) of patients who received posoleucel overall and 75% (6/8) of patients in the biweekly dosing group, achieved a ≥1-log viral load reduction vs. 25% (1/4) of patients in the placebo group Biomarker da
4 - Allovir, Inc. (0001754068) (Issuer)
4 - Allovir, Inc. (0001754068) (Issuer)
4 - Allovir, Inc. (0001754068) (Issuer)
4 - Allovir, Inc. (0001754068) (Issuer)
4 - Allovir, Inc. (0001754068) (Issuer)
4 - Allovir, Inc. (0001754068) (Issuer)
4 - Allovir, Inc. (0001754068) (Issuer)
4 - Allovir, Inc. (0001754068) (Issuer)
4 - Allovir, Inc. (0001754068) (Issuer)
4 - Allovir, Inc. (0001754068) (Issuer)
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) investors that a lawsuit was filed on behalf of investors that purchased AlloVir securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio
- Industry veteran brings more than 25 years of global commercial leadership and cell therapy expertise to AlloVir to build out company's commercial strategy and capabilities - AlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Cintia Piccina, PharmD, MBA, as the company's Chief Commercial Officer, effective June 12, 2023. Ms. Piccina will drive the global commercialization strategy for AlloVir, with a focus on its lead product, posoleucel, and be responsible for building a commercial team in anticipation of a 2025 launch. "Cintia is an accomplished executive with a track record of successful cell therapy and oncology
Company's three posoleucel Phase 3 global registrational trials for three distinct, first-to-market indications continue to enroll with data readouts on track for 2024 Positive results from a randomized, double-blind, placebo-controlled Phase 2 study of posoleucel in kidney transplant recipients with BK viremia will be presented at the American Transplant Congress 2023 later this quarter AlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the first quarter ended March 31, 2023. The company shared progress across its allogeneic, off-the-shelf-virus specific T cell (VST) programs, including its lead investigational th
AlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello brings more than 35 years of broad experience building and leading commercial organizations in the life sciences industry, with specific expertise in cell and gene therapy. "We're thrilled to welcome Shawn to our Board of Directors. Her depth of experience in building successful biopharmaceutical companies and leading innovative cell and gene therapies from clinical development to commercialization is invaluable to AlloVir, as we advance our multi-virus specific T cell platform and evolve into a commercial stage co
- Viralym-M pivotal trial in virus-associated hemorrhagic cystitis continues to progress enrollment - Viralym-M proof-of-concept studies in multi-virus prevention in stem cell transplant and BK viremia in kidney transplant continue to progress with initial data expected 4Q21 - Additional Viralym-M pivotal and proof-of-concept clinical trials expected to initiate in 2H21 - ALVR109 proof-of-concept study in high-risk COVID-19 patients progressing, initial data expected in 4Q21 - ALVR106 IND cleared with proof-of-concept study in RSV, influenza, human metapneumovirus, and parainfluenza expected to initiate in 2H21 - Dr. Diana Brainard's transition from independent director to CEO has comm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that its Board of Directors has appointed Diana M. Brainard, M.D., as the company’s Chief Executive Officer (CEO), effective May 17, 2021. Dr. Brainard has served on AlloVir’s Board of Directors since April 2019, initially as a Board Observer, and as an Independent Director since July 2020. Dr. Brainard currently serves as Senior Vice President and Head of the Virology Therapeutic Area at Gilead Sciences, Inc. She will succeed David Hallal, who will step down as CEO and continue to serve as Executive Chairman of the Board. A physician-scientist specializing in in
BofA Securities downgraded AlloVir from Buy to Underperform and set a new price target of $1.00 from $17.00 previously
Leerink Partners downgraded AlloVir from Outperform to Market Perform
Piper Sandler downgraded AlloVir from Overweight to Neutral
JP Morgan downgraded AlloVir from Overweight to Underweight
BofA Securities initiated coverage of AlloVir with a rating of Buy and set a new price target of $17.00
SVB Leerink reiterated coverage of AlloVir with a rating of Outperform and set a new price target of $30.00 from $32.00 previously
Morgan Stanley reiterated coverage of AlloVir with a rating of Overweight and set a new price target of $45.00 from $48.00 previously
SVB Leerink reiterated coverage of AlloVir with a rating of Outperform and set a new price target of $32.00 from $37.00 previously
SVB Leerink reiterated coverage of AlloVir with a rating of Outperform and set a new price target of $37.00 from $41.00 previously
Morgan Stanley resumed coverage of AlloVir with a rating of Overweight and set a new price target of $48.00
144 - Allovir, Inc. (0001754068) (Subject)
144 - Allovir, Inc. (0001754068) (Subject)
144 - Allovir, Inc. (0001754068) (Subject)
10-Q - Allovir, Inc. (0001754068) (Filer)
425 - Allovir, Inc. (0001754068) (Subject)
425 - Allovir, Inc. (0001754068) (Subject)
425 - Allovir, Inc. (0001754068) (Subject)
425 - Allovir, Inc. (0001754068) (Subject)
425 - Allovir, Inc. (0001754068) (Subject)
425 - Allovir, Inc. (0001754068) (Subject)
SC 13G - Allovir, Inc. (0001754068) (Subject)
SC 13G/A - Allovir, Inc. (0001754068) (Subject)
SC 13G/A - Allovir, Inc. (0001754068) (Subject)
SC 13G/A - Allovir, Inc. (0001754068) (Subject)
SC 13G/A - Allovir, Inc. (0001754068) (Subject)
SC 13G - Allovir, Inc. (0001754068) (Subject)
SC 13G/A - Allovir, Inc. (0001754068) (Subject)
SC 13G - Allovir, Inc. (0001754068) (Subject)
SC 13G/A - Allovir, Inc. (0001754068) (Subject)
SC 13G - Allovir, Inc. (0001754068) (Subject)
The most oversold stocks in the health care presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. iBio, Inc. (NYSE:IBIO) On Dec. 5, iBio announced pricing of a $4.5 million public offering. The company’s stock fell around 11% over the
The move follows AlloVir’s announcement on December 22, 2023 that it is discontinuing its three global Phase 3 posoleucel studies. This workforce reduction will take place primarily during the first quarter of 2024 and expects to be substantially completed by April 15, 2024. As a result of these actions, AlloVir expects to incur personnel-related restructuring charges of approximately $13 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the first quarter of 2024.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. raised Karuna Therapeutics, Inc. (NASDAQ:KRTX) price target from $300 to $330. HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the stock from Buy to Neutral. Karuna Therapeutics shares jumped 47.7% to close at $317.85 on Friday. See how other analysts view this stock. B of A Securities cut the price target for AlloVir, Inc. (NASDAQ:ALVR) from $17 to $1. B of A Securities analyst Jason Zemansky downgraded the stock from Buy to Underperform. AlloVir shares fell 67.2% to
B of A Securities analyst Jason Zemansky downgrades AlloVir (NASDAQ:ALVR) from Buy to Underperform and lowers the price target from $17 to $1.
Gainers Jin Medical International (NASDAQ:ZJYL) shares moved upwards by 94.4% to $137.0 during Monday's regular session. The market value of their outstanding shares is at $1.0 billion. Karuna Therapeutics (NASDAQ:KRTX) stock increased by 47.71% to $317.87. The market value of their outstanding shares is at $11.9 billion. IMAC Hldgs (NASDAQ:BACK) shares moved upwards by 42.59% to $2.31. The market value of their outstanding shares is at $2.6 million. Pasithea Therapeutics (NASDAQ:KTTA) shares rose 32.86% to $0.38. The market value of their outstanding shares is at $7.9 million. PureTech Health (NASDAQ:PRTC) stock moved upwards by 31.3% to $25.0. The market value of their outstanding sha
Gainers Karuna Therapeutics (NASDAQ:KRTX) shares increased by 47.4% to $317.1 during Monday's pre-market session. The company's market cap stands at $11.9 billion. Universe Pharmaceuticals (NASDAQ:UPC) shares rose 30.21% to $1.55. The company's market cap stands at $5.6 million. Senti Biosciences (NASDAQ:SNTI) shares rose 26.97% to $0.56. The company's market cap stands at $24.8 million. Cidara Therapeutics (NASDAQ:CDTX) shares increased by 17.9% to $0.87. The company's market cap stands at $78.6 million. Trinity Biotech (NASDAQ:TRIB) shares increased by 14.14% to $0.51. The company's market cap stands at $19.6 million. Atara Biotherapeutics (NASDAQ:ATRA) stock moved upwards by 13.45%
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Friday. The Dow traded down 0.05% to 37,385.32 while the NASDAQ rose 0.12% to 14,982.36. The S&P 500 also rose, gaining, 0.15% to 4,753.64. Check This Out: $312M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging Sectors Consumer staples shares jumped by 0.9% on Friday. In trading on Friday, consumer discretionary shares fell by 0.3%. Top Headline NIKE, Inc. (NYSE:NKE) posted better-than-expected earnings for its second quarter, but sales missed expectations. Nike reported quarterly earnings of $1.03 per share, surpassing analyst expect
Shares of AAR Corp. (NYSE:AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. AAR reported quarterly sales of $545.4 million, up 16% Y/Y, missing the consensus of $557.2 million. Adjusted EPS from continuing operations rose 17% Y/Y to 81 cents, beating the consensus of 80 cents. AAR recently disclosed the buyout of the Product Support business of Triumph Group Inc (NYSE:TGI) for $725 million. AAR shares fell 7% to $65.82 on Friday. Here are some other stocks moving in today's mid-day session. Gainers NextPlay Technologies, Inc. (NASDAQ:NXTP) shares jumped 263% to $3.29. Jin Medical International Ltd. (NASDAQ:ZJYL) gained 71% to $120.5
Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 85.2% to $130.55 during Friday's regular session. The company's market cap stands at $1.0 billion. Karuna Therapeutics (NASDAQ:KRTX) stock increased by 47.07% to $316.5. The market value of their outstanding shares is at $11.9 billion. IMAC Hldgs (NASDAQ:BACK) shares rose 35.8% to $2.2. The market value of their outstanding shares is at $2.5 million. PureTech Health (NASDAQ:PRTC) shares increased by 28.15% to $24.4. The company's market cap stands at $663.5 million. HeartBeam (NASDAQ:BEAT) stock moved upwards by 24.84% to $2.07. The company's market cap stands at $54.5 million. Neumora Therapeutics (NASDAQ:NMRA) shares increas
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.16% to 37,465.58 while the NASDAQ rose 0.28% to 15,005.25. The S&P 500 also rose, gaining, 0.28% to 4,759.82. Check This Out: $312M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging Sectors Utilities shares jumped by 0.9% on Friday. In trading on Friday, consumer discretionary shares fell by 0.4%. Top Headline The University of Michigan's consumer sentiment was revised higher to 69.7 in December versus a preliminary reading of 69.4. Equities Trading UP Karuna Therapeutics, Inc. (NASDAQ:KRTX)